Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Single Rising Dose Study With Intravenous Infusion and Subcutaneous Injection of BI 1005273 in Healthy Male Volunteers.

This study has been completed.
Information provided by (Responsible Party):
Boehringer Ingelheim Identifier:
First received: July 18, 2012
Last updated: October 14, 2014
Last verified: October 2014
To investigate the safety and tolerability of BI 1005273 in healthy male volunteers following intravenous (i.v.) infusion of single rising doses and subcutaneous (s.c.) injection. Secondary objectives are the exploration of the pharmacokinetics and early pharmacodynamics of BI 1005273.

Condition Intervention Phase
Drug: BI 1005273 s.c.
Drug: BI 105273 i.v. Placebo
Drug: BI 1005273 s.c. Placebo
Drug: BI 1005273 i.v.
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Single Blind
Primary Purpose: Treatment
Official Title: Safety, Tolerability, Pharmacokinetics and Early Pharmacodynamics of Single Rising Intravenous and Subcutaneous Doses of BI 1005273 in Healthy Male Volunteers (Randomised, Single-blind, Placebo-controlled Within Dose Groups, Clinical Phase I Study)

Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • number (% subjects) with drug-related AEs. [ Time Frame: day -21 to day 95 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Cmax (maximum measured concentration of the analyte in plasma) [ Time Frame: day 1 to day 90 ] [ Designated as safety issue: No ]
  • AUC0-8 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) [ Time Frame: day 1 to day 90 ] [ Designated as safety issue: No ]
  • AUC0-tz (area under the concentration-time curve of the analyte in the plasma over the time interval from 0 to the last measurable time point of the dose) [ Time Frame: day 1 to day 90 ] [ Designated as safety issue: No ]

Enrollment: 88
Study Start Date: July 2012
Study Completion Date: September 2014
Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BI 1005273 i.v.
single dose i.v. infusion
Drug: BI 1005273 i.v.
Placebo Comparator: BI 1005273 i.v. Placebo
single dose i.v. infusion (Placebo)
Drug: BI 105273 i.v. Placebo
Experimental: BI 1005273 s.c.
single dose s.c. injection
Drug: BI 1005273 s.c.
Placebo Comparator: BI 1005273 s.c. Placebo
single dose s.c. injection (Placebo)
Drug: BI 1005273 s.c. Placebo


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion criteria:

1. Healthy male subjects

Exclusion criteria:

1. Any deviation from healthy conditions

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01650155

1294.1.1 Boehringer Ingelheim Investigational Site
Berlin, Germany
Sponsors and Collaborators
Boehringer Ingelheim
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Responsible Party: Boehringer Ingelheim Identifier: NCT01650155     History of Changes
Other Study ID Numbers: 1294.1  2011-004987-30 
Study First Received: July 18, 2012
Last Updated: October 14, 2014
Health Authority: Germany: Paul-Ehrlich-Institut processed this record on October 21, 2016